From the past two years, it’s for the third time, the Food and Drug Administration (FDA) has permitted a new weight-loss pill.
This Wednesday, the Contrave got approval from the Food and Drug Administration. Orexigen Therapeutics Inc., San Diego, has made the medication and will be marketed by Takeda Pharmaceutical of Japan. The chemical composition of the Contrave includes the some older drugs and two newer pills, Qsymia and Belviq, in order to help out adults fight their bulges.
There are lots of weight-loss medicines available in the market until now but none of them promise massive weight loss. They actually works by decreasing hunger and all have some side effects and drawbacks.
The FDA’s Jean-Marc Guettier reported in the press release that, obesity continues to be a key community health concern. He also claims that; When Contrave is being used as along with the combination of healthy lifestyle that includes a reduced-calorie diet and exercise, it provides another treatment option.
As compared to Contraves’ competitors, it is permitted for people who are obese or who are flabby and also going through some weight-related health problems, such as diabetes. Contrave is a combination of two drugs: naltrexone, which is also used to treat alcohol and drug dependence, and bupropion, an antidepressant also used as a smoking termination treatment.
FDA says, Contrave comes up with a caution that it may raise suicidal thoughts. Other potential side effects include increases in blood pressure and heart rate.
According to the experiments, patients taking Contrave loss 2% to 4.1% more weight than those taking placebo. Around 36% to 42% lost at least 5% of their body weight with the use of Contrave. Another FDA Belviq’s studies claims that average losses were 3% to 3.7% over placebo; for Qsymia, average losses were 6.7% to 8.9% over placebo.
In terms of potential sufferers, such weight losses can be significant, though it won’t happen if they just rely on pills, says Adam Tsai, a Denver internist who chairs the public affair committee of the Obesity Society, a group representing weight loss experts.
Tsai said that “The ideal candidate for a drug to treat obesity is someone who uses the drug as a tool, along with diet and exercise”.
Until now, the other new pills have not been big sellers. As per the reports of FDA, more than a third of U.S. adults, 78.6 million, are obese.